Cholangiocarcinoma
Showing NaN - NaN of 12
Bile Duct Cancer, Cholangiocarcinoma, Cholangiocarcinoma Non-resectable Trial in Boston (Gemcitabine, Cisplatin, Durvalumab)
Not yet recruiting
- Bile Duct Cancer
- +4 more
- Gemcitabine
- +3 more
-
Boston, MassachusettsBeth Israel Deaconess Medical Center
Jan 23, 2023
Advanced Cancer, Anal Carcinoma, Anal Cancer Trial in Worldwide (pembrolizumab)
Recruiting
- Advanced Cancer
- +24 more
- pembrolizumab
-
Los Angeles, California
- +21 more
Jan 18, 2023
Minimal Residual Disease, KRAS G12D, KRAS G12R Trial in United States (ELI-002 2P)
Recruiting
- Minimal Residual Disease
- +11 more
- ELI-002 2P
-
Duarte, California
- +10 more
Jan 18, 2023
Mesothelioma, Glioblastoma, Renal Cell Carcinoma Trial in Korea, Republic of, Taiwan, United States (NGM707, NGM707 plus
Recruiting
- Mesothelioma
- +14 more
- NGM707
- NGM707 plus pembrolizumab
-
Los Angeles, California
- +13 more
Aug 16, 2022
Cholangiocarcinoma, Hilar Lymphadenopathy, Biliary Stricture Trial in United States (PTBD, ERC)
Terminated
- Cholangiocarcinoma
- +2 more
- PTBD
- ERC
-
Los Angeles, California
- +24 more
Mar 23, 2020
Cholangiocarcinoma Trial in Austria, United States (Nab-Paclitaxel and Gemcitabine)
Completed
- Cholangiocarcinoma
- Nab-Paclitaxel and Gemcitabine
-
Denver, Colorado
- +24 more
Sep 5, 2018
Carcinoma of Intrahepatic and Extra-hepatic Biliary System, Carcinoma of Gallbladder, Bile Duct Cancer Trial in United States
Completed
- Carcinoma of Intrahepatic and Extra-hepatic Biliary System
- +3 more
- DKN-01
- +2 more
-
Los Angeles, California
- +8 more
Sep 6, 2018
Cholangiocarcinoma, Pancreatic Cancer, Bile Duct Cancer Trial in Boston, New York (Radio Frequency ablation Probe)
Unknown status
- Cholangiocarcinoma
- +4 more
- Radio Frequency ablation Probe
-
Boston, Massachusetts
- +1 more
Feb 16, 2017